Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Profusa, Inc. Common Stock

PFSA

Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.

Last trade $0.3397
Day change -$0.066 (-16.27%)
Day range $0.32 – $0.396
Volume 194,521
Market cap $0M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$248.32K
Price / earnings
—
Price / book
0.03×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.2×

Profitability

Earnings per share
-$42.48
Return on assets
-89.06%
Return on equity
-330.06%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.39×
Current ratio
0.02×
Quick ratio
0.02×
Cash ratio
0.02×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.1M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PFSA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025
Revenue$0$0$0$0$0
Cost of revenue$0$0$0$0$0
Gross profit$0$0$0$0$0
Selling, general and administrative$4.63M$1.72M$2.86M$2.32M$20.99M
Research and development$222K$823K$1.15M$1.26M$722K
Total operating expenses$4.85M$2.55M$4.01M$3.57M$21.71M
Operating income-$4.85M-$2.55M-$4.01M-$3.57M-$21.71M
Interest expense-$25K-$2.43M-$78K-$2.6M-$1.61M
Income before taxes-$4.95M-$8.76M-$3.46M-$8.57M-$26.09M
Income taxes$0$0$0$0$0
Net income-$4.95M-$8.76M-$3.46M-$8.57M-$26.09M
Net income attributable to common shareholders-$4.95M-$8.76M-$3.46M-$8.57M-$26.09M
EBITDA-$4.85M-$2.54M-$4.01M-$3.57M-$21.71M
Basic earnings per share-$6.23-$151.80-$2.05—-$6,167.85
Diluted earnings per share-$6.23-$151.80-$2.05—-$6,167.85

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform

Profusa has submitted a comprehensive response package to its European Notified Body GMED following successful completion of Stage 1 and Stage 2 assessments for CE Mark certification of its Lumee Oxygen Platform. The submission includes updates to technical documentation, quality system evidence, clinical evaluation activities, and validation information. The company remains committed to obtaining CE Mark certification to support European commercialization of its tissue oxygen monitoring technology.

GlobeNewswire Inc.

Profusa Receives Favorable Nasdaq Listing Determination

Profusa, Inc. (PFSA) has been granted approval by the Nasdaq Hearings Panel to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market. The company must satisfy interim milestones and comply with bid price and stockholders' equity requirements by July 6, 2026, to maintain its continued listing.

Benzinga

What's Going On With Profusa Stock Tuesday?

Profusa (NASDAQ: PFSA) shares plummeted 40.27% on Tuesday following the announcement of a Letter of Intent to acquire BioInsights' PanOmics multi-omics diagnostics platform for approximately $30 million in an all-equity deal. The acquisition marks Profusa's strategic expansion into molecular diagnostics and aims to complement its Lumee real-time biochemistry monitoring system, with initial commercialization targeting pancreatic cancer.

Benzinga

Profusa Stock Soars On Deal Targeting Multi Billion Precision Diagnostics Space

Profusa announced an all-equity acquisition of BioInsights LLC's PanOmics multi-omics diagnostics platform, expanding into precision diagnostics. The deal adds $30 million to shareholder equity and accelerates commercialization through integration with Profusa's Lumee platform. The company is also advancing a Mayo Clinic collaboration for pancreatic cancer applications. Profusa shares surged 134.99% in premarket trading.

GlobeNewswire Inc.

Profusa Bolsters European Commercial Network with New French Distributor, MedSell

Profusa announced a new distributor partnership with MedSell in France to commercialize its Lumee Oxygen tissue monitoring device for critical limb threatening ischemia (CLTI) patients. This partnership, combined with existing distributors across Europe, now covers approximately 200,000 annual CLI cases in the EU. The company projects $0.5-$2 million revenue in 2026 and $9-$13 million in 2027, with plans to reach $200-$250 million by 2030.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 17, 20261-for-4reverse split
Jul 7, 20261-for-25reverse split
Feb 9, 20261-for-75reverse split